Gemcitabine Combination Nano Therapies for Pancreatic Cancer.
Gemcitabine
chemotherapy
combination therapy
drug resistance
nanoparticles
Journal
Pharmaceutics
ISSN: 1999-4923
Titre abrégé: Pharmaceutics
Pays: Switzerland
ID NLM: 101534003
Informations de publication
Date de publication:
04 Nov 2019
04 Nov 2019
Historique:
received:
10
10
2019
revised:
28
10
2019
accepted:
28
10
2019
entrez:
7
11
2019
pubmed:
7
11
2019
medline:
7
11
2019
Statut:
epublish
Résumé
Pancreatic cancer is one of the deadliest causes of cancer-related death in the United States, with a 5-year overall survival rate of 6 to 8%. These statistics suggest that immediate medical attention is needed. Gemcitabine (GEM) is the gold standard first-line single chemotherapy agent for pancreatic cancer but, after a few months, cells develop chemoresistance. Multiple clinical and experimental investigations have demonstrated that a combination or co-administration of other drugs as chemotherapies with GEM lead to superior therapeutic benefits. However, such combination therapies often induce severe systemic toxicities. Thus, developing strategies to deliver a combination of chemotherapeutic agents more securely to patients is needed. Nanoparticle-mediated delivery can offer to load a cocktail of drugs, increase stability and availability, on-demand and tumor-specific delivery while minimizing chemotherapy-associated adverse effects. This review discusses the available drugs being co-administered with GEM and the limitations associated during the process of co-administration. This review also helps in providing knowledge of the significant number of delivery platforms being used to overcome problems related to gemcitabine-based co-delivery of other chemotherapeutic drugs, thereby focusing on how nanocarriers have been fabricated, considering the modes of action, targeting receptors, pharmacology of chemo drugs incorporated with GEM, and the differences in the physiological environment where the targeting is to be done. This review also documents the focus on novel mucin-targeted nanotechnology which is under development for pancreatic cancer therapy.
Identifiants
pubmed: 31689930
pii: pharmaceutics11110574
doi: 10.3390/pharmaceutics11110574
pmc: PMC6920852
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Subventions
Organisme : NCI NIH HHS
ID : R01 CA204552
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA206069
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA210192
Pays : United States
Organisme : Herb Kosten Foundation
ID : Pancreatic Cancer Funding
Références
Invest New Drugs. 1992 Aug;10(3):165-70
pubmed: 1428726
Am J Health Syst Pharm. 1997 Jan 15;54(2):162-70; quiz 197-8
pubmed: 9117804
Urol Oncol. 2008 Jan-Feb;26(1):57-64
pubmed: 18190833
Nanomedicine (Lond). 2012 Aug;7(8):1225-33
pubmed: 22931448
J Control Release. 2013 Sep 10;170(2):268-78
pubmed: 23756152
J Clin Pharmacol. 2014 Oct;54(10):1097-107
pubmed: 24719309
Int J Nanomedicine. 2008;3(2):277-86
pubmed: 18686787
J Control Release. 2016 May 10;229:183-191
pubmed: 27016140
Cancer Chemother Pharmacol. 2016 Jul;78(1):1-12
pubmed: 27007129
J Biomed Nanotechnol. 2016 Aug;12(8):1654-66
pubmed: 29342344
J Control Release. 2000 Mar 1;65(1-2):271-84
pubmed: 10699287
Cancer Res. 1991 Nov 15;51(22):6110-7
pubmed: 1718594
Semin Oncol. 1995 Aug;22(4 Suppl 11):3-10
pubmed: 7481842
AAPS PharmSciTech. 2018 Feb;19(2):693-699
pubmed: 28971370
Mol Cancer Ther. 2012 Jan;11(1):24-33
pubmed: 22027689
J Control Release. 2015 Mar 10;201:90-9
pubmed: 25620067
J Clin Oncol. 2011 Dec 1;29(34):4548-54
pubmed: 21969517
ACS Nano. 2013 Nov 26;7(11):10048-65
pubmed: 24143858
World J Oncol. 2019 Feb;10(1):10-27
pubmed: 30834048
ACS Nano. 2015;9(4):3540-57
pubmed: 25776964
Pharm Res. 2010 Dec;27(12):2569-89
pubmed: 20725771
Anticancer Drugs. 1995 Dec;6 Suppl 6:27-32
pubmed: 8718422
Bioconjug Chem. 2012 May 16;23(5):966-80
pubmed: 22471294
Front Pharmacol. 2015 Dec 01;6:286
pubmed: 26648870
Nat Biotechnol. 2015 Sep;33(9):941-51
pubmed: 26348965
Int J Pharm. 2016 Nov 20;513(1-2):564-571
pubmed: 27613255
Biomacromolecules. 2016 Jan 11;17(1):301-13
pubmed: 26626700
J Neuroimmune Pharmacol. 2017 Mar;12(1):6-16
pubmed: 27270720
J Pathol. 1996 Oct;180(2):160-5
pubmed: 8976874
Biomaterials. 2015 Apr;46:13-25
pubmed: 25678112
J Clin Oncol. 1991 Mar;9(3):491-8
pubmed: 1999720
Biomaterials. 2011 Nov;32(32):8281-90
pubmed: 21807411
Cancers (Basel). 2017 Apr 28;9(5):
pubmed: 28452926
Oncogene. 2008 Jul 24;27(32):4402-10
pubmed: 18469851
J Control Release. 2015 Jun 10;207:77-85
pubmed: 25863273
Curr Pharm Des. 2016;22(19):2796-807
pubmed: 26898742
Therap Adv Gastroenterol. 2017 Jul;10(7):563-572
pubmed: 28804517
Proc Natl Acad Sci U S A. 2014 Aug 19;111(33):12181-6
pubmed: 25092316
Nat Rev Cancer. 2017 Jan;17(1):20-37
pubmed: 27834398
Int J Pharm. 2019 Mar 25;559:220-227
pubmed: 30703501
Chem Rev. 1999 Sep 8;99(9):2293-352
pubmed: 11749483
Indian J Surg Oncol. 2015 Mar;6(1):75-81
pubmed: 25937768
ACS Nano. 2013 Mar 26;7(3):2078-89
pubmed: 23402593
Eur J Pharm Biopharm. 2008 May;69(1):1-9
pubmed: 17826969
Cancer Discov. 2012 Mar;2(3):260-269
pubmed: 22585996
J Control Release. 2013 Jul 10;169(1-2):62-72
pubmed: 23588390
Future Oncol. 2010 Aug;6(8):1313-23
pubmed: 20799876
Pancreatology. 2019 Jan;19(1):64-72
pubmed: 30396819
Cancer Res. 1986 Dec;46(12 Pt 1):6387-92
pubmed: 2946403
J Control Release. 2014 Sep 28;190:485-99
pubmed: 24984011
Oncotarget. 2017 May 17;8(32):53854-53872
pubmed: 28881856
Pathol Res Pract. 2019 Apr;215(4):755-760
pubmed: 30718098
Mater Sci Eng C Mater Biol Appl. 2013 Apr 1;33(3):1183-92
pubmed: 23827558
Nano Lett. 2008 May;8(5):1492-500
pubmed: 18412402
Mol Pharm. 2017 Sep 5;14(9):3121-3133
pubmed: 28719220
Mol Ther. 2013 Aug;21(8):1559-69
pubmed: 23774791
Drug Des Devel Ther. 2018 Jul 02;12:1959-1975
pubmed: 29997433
Cancer Res. 2008 Mar 15;68(6):1970-8
pubmed: 18339879
Anticancer Drugs. 2018 Aug;29(7):637-645
pubmed: 29846247
Expert Opin Drug Deliv. 2011 Dec;8(12):1609-29
pubmed: 22077480
Nanoscale. 2015 Nov 28;7(44):18411-23
pubmed: 26508277
J Clin Oncol. 2006 Aug 20;24(24):3946-52
pubmed: 16921047
Adv Drug Deliv Rev. 2010 Feb 17;62(2):203-30
pubmed: 19951732
Nanomedicine (Lond). 2015;10(18):2819-32
pubmed: 26377155
Int J Gynecol Cancer. 2006 Jan-Feb;16(1):222-30
pubmed: 16445637
Pharm Res. 1995 Oct;12(10):1407-16
pubmed: 8584472
Cancer Chemother Pharmacol. 2008 Mar;61(3):395-405
pubmed: 17554540
J Drug Target. 2015;23(7-8):759-67
pubmed: 26453171
Mol Pharm. 2017 May 1;14(5):1365-1372
pubmed: 27798825
J Mater Chem B. 2014 Oct 14;2(38):6560-6570
pubmed: 32261817
J Clin Oncol. 1997 Jun;15(6):2403-13
pubmed: 9196156
ACS Appl Bio Mater. 2019 Mar 18;2(3):1298-1309
pubmed: 35021377
Drugs. 1997 Sep;54(3):447-72
pubmed: 9279506
Front Physiol. 2013 Dec 17;4:370
pubmed: 24381558
Anticancer Res. 2017 Nov;37(11):6031-6039
pubmed: 29061782
Nanomedicine. 2018 Jul;14(5):1629-1641
pubmed: 29684527
Mol Pharm. 2018 Mar 5;15(3):1203-1214
pubmed: 29397747
J Control Release. 2012 Jul 20;161(2):152-63
pubmed: 22001607
World J Gastrointest Oncol. 2018 Oct 15;10(10):317-327
pubmed: 30364837
Adv Healthc Mater. 2015 May;4(7):1092-103
pubmed: 25721343
Biomaterials. 2009 Jul;30(20):3466-75
pubmed: 19304320
Acta Biomater. 2016 Mar;33:34-9
pubmed: 26826531
Cancer Res. 2006 May 1;66(9):4553-7
pubmed: 16651403
Drug Des Devel Ther. 2017 Sep 05;11:2631-2642
pubmed: 28919713
Sci Transl Med. 2015 Nov 18;7(314):314ra183
pubmed: 26582898
N Engl J Med. 2013 Oct 31;369(18):1691-703
pubmed: 24131140
Br J Cancer. 2009 Oct 6;101(7):1155-61
pubmed: 19738614
J Control Release. 2017 Aug 10;259:149-159
pubmed: 27865562
P T. 2017 Dec;42(12):742-755
pubmed: 29234213
Biomaterials. 2015;53:763-74
pubmed: 25890771
Artif Cells Nanomed Biotechnol. 2017 Dec;45(8):1530-1538
pubmed: 27894196
Adv Drug Deliv Rev. 2013 Jan;65(1):36-48
pubmed: 23036225
SAGE Open Med Case Rep. 2018 Oct 30;6:2050313X18809268
pubmed: 30397477